Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00314860 · ClinicalTrials.gov registry record · Phase 3
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 568
- Enrollment target
NCT00314860 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 568 participants.
The verdict
NCT00314860, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 568 participants
- Enrollment target
Study Summary
Restless Legs Syndrome (RLS) study in adults comparing immediate release ropinirole with extended release ropinirole over 12 weeks
Interventions
- DRUG ropinirole Extended Release (XR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 568 participants |
| Start Date | 2006-02 |
| Est. Completion | 2006-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00314860
The ClinicalTrials.gov registry entry for NCT00314860 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 568 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ropinirole Extended Release (XR) is the first listed.
NCT00314860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00314860 about?
NCT00314860 is a clinical study titled "RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole". Restless Legs Syndrome (RLS) study in adults comparing immediate release ropinirole with extended release ropinirole over 12 weeks
What is the current status of trial NCT00314860?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 568 participants. The study started on 2006-02. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00314860?
The interventions under investigation include: ropinirole Extended Release (XR) (DRUG).
Who is sponsoring clinical trial NCT00314860?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.